País: África do Sul
Língua: inglês
Origem: South African Health Products Regulatory Authority (SAHPRA)
Bm_squib
INDICATIONS [/za_1131.html#1] [/za_1131.html#1] [/za_1131.html#1] CONTRA-INDICATIONS [/za_1131.html#1] [/za_1131.html#1] DOSAGE [/za_1131.html#1] [/za_1131.html#1] SIDE-EFFECTS [/za_1131.html#1] [/za_1131.html#1] [/za_1131.html#1] PREGNANCY [/za_1131.html#1] [/za_1131.html#1] OVERDOSE [/za_1131.html#1] IDENTIFICATION [/za_1131.html#1] [/za_1131.html#1] PATIENT INFORMATION FUNGIZONE INTRAVENOUS SCHEDULING STATUS: S4 PP ZIMBABWE ONLY PROPRIETARY NAME (and dosage form): FUNGIZONE INTRAVENOUS INJECTION COMPOSITION FUNGIZONE Intravenous ( AMPHOTERICIN B for injection) is a sterile lyophilized powder providing 50 mg amphotericin B and 41 mg sodium desoxycholate with 20,2 mg sodium phosphate as a buffer, per vial. At the time of manufacture, the air in the container is replaced by nitrogen. PHARMACOLOGICAL CLASSIFICATION Category A 20.1.7 (Antifungal Antibiotics). PHARMACOLOGICAL ACTION MICROBIOLOGY Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0,03 to 1,0 micrograms/mL in vitro. The antibiotic is without effect on bacteria, rickettsiae and viruses. HUMAN PHARMACOLOGY Amphotericin B is fungistatic rather than fungicidal in concentrations obtainable in body fluids. It probably acts by binding to sterols in the fungal cell membrane of susceptible fungi with a resultant change in membrane permeability which allows leakage of intracellular components. Mammalian cell membranes also contain sterols and it has been suggested that the damage to human cells (toxicity Leia o documento completo